| Fine Digestive Health | |
|
6750 N Macarthur Blvd Ste 300 Irving TX 75039 | |
| (972) 253-4205 | |
| Not Available |
| Full Name | Fine Digestive Health |
|---|---|
| Speciality | Internal Medicine |
| Location | 6750 N Macarthur Blvd Ste 300, Irving, Texas |
| Authorized Official Name and Position | David Bennett (OFFICE MANAGER) |
| Authorized Official Contact | 8175718181 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Fine Digestive Health 6750 N Macarthur Blvd Ste 300 Irving TX 75039-2473 Ph: (972) 401-2335 | Fine Digestive Health 6750 N Macarthur Blvd Ste 300 Irving TX 75039 Ph: (972) 253-4205 |
| NPI Number | 1063909034 |
|---|---|
| Provider Enumeration Date | 04/16/2018 |
| Last Update Date | 08/17/2018 |
| Medicare PECOS PAC ID | 9436406691 |
|---|---|
| Medicare Enrollment ID | O20180718002935 |
News Archive
A research group led by MANA Scientist Kohsaku Kawakami, postdoctoral researcher Shaoling Zhang and MANA Principal Investigator Katsuhiko Ariga, at the International Center for Materials Nanoarchitectonics (MANA), NIMS (Sukekatsu Ushioda, President), succeeded in developing porous particles (mesoporous particles) consisting solely of phospholipids, a biological component, that are suitable for use as a drug delivery system.
Benefitfocus today announced the acquisition of BeliefNetworks, Inc., a leader in transforming real-time data – including consumer behavior, marketing campaign data and social networking conversations – into actionable knowledge for customers. The agreement includes three patent applications and proprietary software code. These assets and the highly-experienced staff of BeliefNetworks are a valuable addition to Benefitfocus, the leader in Software as a Service solutions for health and voluntary benefits.
A new MedUni Vienna study conducted in the Comprehensive Cancer Centre (CCC) Vienna shows that certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063909034 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | M6131 (Texas) | Primary |
| Provider Name | Jeffrey S Fine |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1649272816 PECOS PAC ID: 0042276248 Enrollment ID: I20061102000556 |
News Archive
A research group led by MANA Scientist Kohsaku Kawakami, postdoctoral researcher Shaoling Zhang and MANA Principal Investigator Katsuhiko Ariga, at the International Center for Materials Nanoarchitectonics (MANA), NIMS (Sukekatsu Ushioda, President), succeeded in developing porous particles (mesoporous particles) consisting solely of phospholipids, a biological component, that are suitable for use as a drug delivery system.
Benefitfocus today announced the acquisition of BeliefNetworks, Inc., a leader in transforming real-time data – including consumer behavior, marketing campaign data and social networking conversations – into actionable knowledge for customers. The agreement includes three patent applications and proprietary software code. These assets and the highly-experienced staff of BeliefNetworks are a valuable addition to Benefitfocus, the leader in Software as a Service solutions for health and voluntary benefits.
A new MedUni Vienna study conducted in the Comprehensive Cancer Centre (CCC) Vienna shows that certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
› Verified 4 days ago
News Archive
A research group led by MANA Scientist Kohsaku Kawakami, postdoctoral researcher Shaoling Zhang and MANA Principal Investigator Katsuhiko Ariga, at the International Center for Materials Nanoarchitectonics (MANA), NIMS (Sukekatsu Ushioda, President), succeeded in developing porous particles (mesoporous particles) consisting solely of phospholipids, a biological component, that are suitable for use as a drug delivery system.
Benefitfocus today announced the acquisition of BeliefNetworks, Inc., a leader in transforming real-time data – including consumer behavior, marketing campaign data and social networking conversations – into actionable knowledge for customers. The agreement includes three patent applications and proprietary software code. These assets and the highly-experienced staff of BeliefNetworks are a valuable addition to Benefitfocus, the leader in Software as a Service solutions for health and voluntary benefits.
A new MedUni Vienna study conducted in the Comprehensive Cancer Centre (CCC) Vienna shows that certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
› Verified 4 days ago
Sunil Mathews, Md Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7701 Las Colinas Rdg Ste 260, Irving, TX 75063 Phone: 972-869-3448 Fax: 972-459-7729 | |
Family Medicine And Research Center Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1625 N Story Rd Ste 148, Family Medicine And Research Center, Irving, TX 75061 Phone: 469-952-8052 | |
Irving Eyecare Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 708 N Macarthur Blvd, Irving, TX 75061 Phone: 972-254-0033 Fax: 972-254-0055 | |
Reliant Health, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1302 Lane St, Suite # 300, Irving, TX 75061 Phone: 817-808-3443 Fax: 817-887-5522 | |
Your Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1141 Kinwest Pkwy, Suite 100, Irving, TX 75063 Phone: 214-239-2222 Fax: 214-239-2223 | |
Evernorth Care Providers - Delaware Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 320 Decker Dr, Irving, TX 75062 Phone: 773-292-4800 Fax: 312-564-4059 | |
Do Not Use Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1706 W Irving Blvd, Irving, TX 75061 Phone: 972-254-1474 Fax: 972-259-3037 |